Prostate-specific antigen (PSA) is a protein produced by both normal and cancerous cells in the prostate gland. It is primarily measured through a blood test, where normal levels are typically found ...

THIS YEAR, IT’S estimated that nearly 300,000 new prostate cancer cases will be diagnosed. While there’s no single test to detect prostate cancer, doctors commonly use the prostate-specific antigen ...

An Italian oncologic psychologist warns these patients: “A prostatectomy doesn’t cure anxiety.” Emotional distress can be so ...

In a study involving more than 11,000 men enrolled in the Prostate, Lung, Colorectal, and Ovarian (PLCO) cancer screening trial, about one quarter of elevated prostate-specific antigen (PSA) results ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Employing MRI-targeted biopsy instead of systematic biopsy reduces overdiagnosis of low-grade prostate cancer by more than half, although diagnoses may be delayed among a small minority of patients ...

An article about the importance of PSA testing for early detection and treatment of prostate cancer ...

High pre-treatment PSA levels correlate with increased recurrence and treatment failure in intermediate-risk prostate cancer patients treated with HIFU. Gleason grade 3 or higher is associated with ...

Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year.